For the quarter ending 2025-09-30, LNTH had -$313,558K decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Gain on interest rate swap termination | - | - | - | 0 |
| Net income | 27,771 | 78,755 | 72,945 | -11,790 |
| Depreciation, amortization and accretion | 20,408 | 13,231 | 13,626 | 17,285 |
| Changes in fair value of contingent assets and liabilities | - | - | - | -1,294 |
| Impairment of long-lived assets | - | - | - | 0 |
| Adjustment to the fair value of asset retirement obligation | 0 | 0 | -4,727 | - |
| Amortization of debt-related costs | 1,113 | 1,115 | 1,115 | 1,079 |
| Change in fair value of contingent assets and liabilities | -982 | - | - | - |
| Inventory adjustments | 1,933 | 2,314 | -1,378 | -1,642 |
| Loss on extinguishment of debt | - | - | - | 0 |
| Stock-based compensation | 24,501 | 22,321 | 21,198 | 22,164 |
| Gain on disposal of assets | 0 | 0 | 0 | 2,161 |
| Unrealized gain on investment in equity securities | 1,160 | 14,573 | -14,862 | -119,056 |
| Charges incurred pursuant to acquired in-process research and development | 0 | 0 | -5,413 | 0 |
| Deferred taxes | 28,956 | -6,928 | 1,351 | -25,627 |
| Long-term income tax payable and other long-term liabilities | -2,751 | -642 | 639 | 2,617 |
| Other long-term assets | - | - | - | -353 |
| Other | -2,259 | -2,441 | -822 | -5,022 |
| Other current assets | - | - | 528 | -3,105 |
| Accounts receivable | -12,830 | 2,288 | 26,363 | -7,202 |
| Inventory | 915 | 5,688 | -278 | -4,431 |
| Other current and noncurrent assets | 4,428 | 1,916 | - | - |
| Long-term indemnification receivable | - | - | - | 0 |
| Accounts payable | 20,108 | 4,383 | 4,982 | -9,955 |
| Asset retirement obligation acceleration | - | - | - | 0 |
| Accrued expenses and other current and noncurrent liabilities | -26,313 | -5,947 | 3,328 | 28,238 |
| Deposit for acquisition of a business | - | - | 50,000 | - |
| Acquisition of evergreen, net of cash acquired | - | 269,098 | - | - |
| Net cash provided by operating activities | 105,294 | 87,106 | 107,563 | 157,730 |
| Capital expenditures | 10,622 | 7,961 | 8,718 | 16,369 |
| Acquisition of in-process research and development | 0 | 5,413 | - | - |
| Proceeds from sale of assets | 0 | 0 | 0 | 9,767 |
| Acquisition of assets, net | 0 | 0 | - | 0 |
| Acquisition, net of cash acquired-Evergreen Theragnostics | 268,933 | - | - | - |
| Acquisition, net of cash acquired-Life Molecular Imaging Ltd | 309,011 | - | - | - |
| Purchases of investment in equity securities | 0 | 0 | 5,000 | 0 |
| Acquisition of exclusive license option | 0 | 0 | 0 | 0 |
| Net cash used in investing activities | -319,468 | -232,472 | -63,718 | -6,602 |
| Payments of long-term debt and other borrowings | 292 | 63 | 402 | -58 |
| Proceeds from stock option exercises | 142 | 2,445 | 3,886 | -494 |
| Proceeds from issuance of long-term debt, net | - | - | - | 0 |
| Proceeds from issuance of common stock | - | - | 1,983 | 0 |
| Proceeds from employee stock purchase plan | 1,743 | 1,983 | - | - |
| Payments for minimum statutory tax withholding related to net share settlement of equity awards | 759 | 795 | 23,686 | 892 |
| Debt issuance costs | - | - | - | 0 |
| Repurchase of common stock | 100,000 | 100,000 | - | 100,000 |
| Contingent value rights settlement | - | - | - | 0 |
| Proceeds from interest rate swap termination | - | - | - | 0 |
| Deferred financing costs | - | - | - | 2,331 |
| Net cash used in financing activities | -99,166 | -98,413 | -18,219 | -103,659 |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | -218 | 827 | 102 | -1,032 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -313,558 | -242,952 | 25,728 | 46,437 |
| Cash and cash equivalents at beginning of period | 914,486 | - | - | - |
| Cash and cash equivalents at end of period | 383,704 | - | - | - |
Lantheus Holdings, Inc. (LNTH)
Lantheus Holdings, Inc. (LNTH)